Mehta Vedant Kamal
Overview
Explore the profile of Mehta Vedant Kamal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamal M, Damerla R, Parida P, Chakrabarty S, Rao M, Kumar N
Cancer Sci
. 2024 Apr;
115(6):2012-2022.
PMID: 38602182
Locally advanced oral squamous cell carcinoma poses a significant challenge in oncology due to its rising incidence and mortality rates. Despite therapeutic progress, understanding molecular intricacies is essential. This study...
2.
Kamal M, Damerla R, Parida P, Rao M, Belle V, Dikhit P, et al.
Cancer Med
. 2024 Mar;
13(3):e6986.
PMID: 38426619
Background: PTGS2 encodes cyclooxygenase-2 (COX-2), which catalyses the committed step in prostaglandin synthesis. Various in vivo and in vitro data suggest that COX-2 mediates the VEGF signalling pathway. In silico...
3.
Parida P, Lewis S, Sharan K, Kamal M, Kumar N, Godkhindi V, et al.
Cells
. 2023 Nov;
12(21).
PMID: 37947608
, also known as URCL4, has been reported to have higher expression and be associated with poor prognosis in lung adenocarcinoma patients, and its role in regulation of the EGFR/AKT/mTORC1...
4.
Kamal M, Damerla R, Dikhit P, Kumar N
J Oral Biol Craniofac Res
. 2023 Aug;
13(5):567-574.
PMID: 37559688
Introduction: The PTGS2 gene codes for the cyclooxygenase-2 (COX-2) enzyme that catalyzes the committed step in prostaglandin (PG) synthesis. Various and data suggest that prostaglandin E2 mediates as a signaling...
5.
Kamal M, Rao M, Damerla R, Pai A, Sharan K, Palod A, et al.
Cancer Invest
. 2022 Oct;
41(2):144-154.
PMID: 36269850
The combination of low-dose methotrexate and celecoxib as metronomic chemotherapy (MCT) is a novel therapy, believed to act by modulating the immune response, inhibiting angiogenesis and its cytotoxic action, though...